Turnstone Biologics (NASDAQ:TSBX), Inc. (NASDAQ: TSBX) is a clinical‐stage biotechnology company dedicated to developing oncolytic viral therapies that harness and enhance the body’s immune system to fight cancer. By leveraging its proprietary Viral Immunotherapy Platform (VIP), Turnstone engineers natural viruses to selectively infect and kill tumor cells while stimulating robust anti‐tumor immune responses. The company’s lead investigational therapy, V937, is derived from Coxsackievirus A21 and is being evaluated in multiple clinical trials for solid tumors, including melanoma and bladder cancer, both as a monotherapy and in combination with immune checkpoint inhibitors.
Turnstone’s research and development efforts focus on both intrinsic and extrinsic tumor vulnerabilities. Its platform allows for the rapid design and testing of viral vectors that can carry therapeutic payloads or express immunomodulatory proteins directly within the tumor microenvironment. This approach is intended to overcome resistance mechanisms that limit the efficacy of existing immunotherapies. In addition to V937, the company is advancing a pipeline of next‐generation candidates designed to optimize dosing, enhance systemic delivery and improve safety profiles.
Founded in 2009 and headquartered in Seattle, Washington, Turnstone Biologics operates research facilities in both the United States and the United Kingdom, enabling collaboration with leading academic institutions and biopharmaceutical partners. The company’s global footprint supports ongoing clinical studies in North America and Europe, and it has established strategic alliances with major industry players to explore combination regimens and broaden the potential application of its oncolytic platforms.
Turnstone’s leadership team combines expertise in virology, oncology and pharmaceutical development. Co‐founder and Chief Executive Officer Hassan F. Merheb brings extensive experience in gene therapy and viral vector engineering, while its board includes renowned immunologists and biotech entrepreneurs who guide the company’s strategic vision. Together, they aim to translate Turnstone’s innovative viral immunotherapies into new treatment options for patients with advanced cancers.
